ACRIVON
LIVE

Serial Number

99388089

Owner

Acrivon Therapeutics, Inc.

Attorney

Sara Bauer

Filing Date

Sep 11, 2025

Add to watchlist:

No watchlists yet
View on USPTO

ACRIVON Trademark

Serial Number: 99388089

ACRIVON is a trademark filed by Acrivon Therapeutics, Inc. on September 11, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Acrivon Therapeutics, Inc. (6 trademarks)

480 Arsenal Way, Suite 100
Watertown, MA 02472

Entity Type: 03

Trademark Details

Filing Date

September 11, 2025

Registration Date

Not Registered

Published for Opposition

March 3, 2026

Goods & Services

Pharmaceutical preparations for the treatment and prevention of cancer, fibrotic, inflammatory, autoimmune, metabolic, infectious, and central nervous system diseases; Protein arrays for diagnosing cancer; Pharmaceutical preparations for the prediction of drug treatment efficacy; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; Diagnostic kits comprising diagnostic agents, preparations and substances for medical purposes; Reagents for medical purposes; Medical diagnostic reagents for use in drug-tailored efficacy predication and analysis; Diagnostic agents, preparations and substances for medical purposes; Diagnostic biomarker reagents for medical purposes; Diagnostic preparations for medical purposes; Diagnostic preparations for medical purposes for detecting genetic predispositions; Biological preparations for the prevention and treatment of cancer, fibrotic, inflammatory, autoimmune, metabolic, infectious, and central nervous system diseases

Medical services; Medical testing services; Medical diagnostic testing, monitoring and reporting services; Medical testing services relating to the diagnosis and treatment of disease; Medical testing for diagnostic or treatment purposes in the field of oncology, fibrotic, inflammatory, autoimmune, metabolic, infectious, and central nervous system diseases; Medical counseling; Providing medical information to medical professional in the form of reports in the field of oncology and precision medicine; Providing a website featuring information in the field of oncology, fibrotic, inflammatory, autoimmune, metabolic, infectious, and central nervous system diseases and precision medicine health

Medical and scientific research in the field of oncology; Medical and scientific research in the field of proteomics, biomarker discovery, rational drug design in drug discovery, patient responder identification and indication finding, and precision medicine clinical trials based on responder identification; Biochemical analysis services in the field of biomarker discovery; Providing medical testing services and information in the field of cancer research and disease classification; Scientific research in the field of pharmaceuticals, therapeutics, and drug formulation and delivery; Scientific research in the field of proteomics and biomarker discovery; Consulting services in the field of pharmaceutical research and development; Pharmaceutical research services; Research and development in the pharmaceutical and biotechnology fields

Filing History

EXTENSION OF TIME TO OPPOSE RECEIVED
Apr 2, 2026 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 3, 2026 NPUB
PUBLISHED FOR OPPOSITION
Mar 3, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 25, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 5, 2026 CNSA
EXAMINER'S AMENDMENT ENTERED
Feb 5, 2026 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 5, 2026 GNEN
EXAMINERS AMENDMENT E-MAILED
Feb 5, 2026 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 5, 2026 CNEA
ASSIGNED TO EXAMINER
Feb 4, 2026 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 3, 2026 NWOS
APPLICATION FILING RECEIPT MAILED
Sep 11, 2025 MAFR
NEW APPLICATION ENTERED
Sep 11, 2025 NWAP